- Home
- NDLS vs IRD Comparison
NDLS vs IRD Comparison
Compare NDLS & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- IRD
- Stock Information
- Founded
- NDLS 1995
- IRD 2018
- Country
- NDLS United States
- IRD United States
- Employees
- NDLS N/A
- IRD N/A
- Industry
- NDLS Restaurants
- IRD
- Sector
- NDLS Consumer Discretionary
- IRD
- Exchange
- NDLS Nasdaq
- IRD NYSE
- Market Cap
- NDLS 34.3M
- IRD 35.7M
- IPO Year
- NDLS 2013
- IRD N/A
- Fundamental
- Price
- NDLS $1.20
- IRD $0.94
- Analyst Decision
- NDLS Strong Buy
- IRD Strong Buy
- Analyst Count
- NDLS 2
- IRD 1
- Target Price
- NDLS $3.00
- IRD $8.00
- AVG Volume (30 Days)
- NDLS 156.5K
- IRD 140.8K
- Earning Date
- NDLS 03-06-2025
- IRD 03-18-2025
- Dividend Yield
- NDLS N/A
- IRD N/A
- EPS Growth
- NDLS N/A
- IRD N/A
- EPS
- NDLS N/A
- IRD N/A
- Revenue
- NDLS $493,271,000.00
- IRD $8,381,000.00
- Revenue This Year
- NDLS $2.24
- IRD N/A
- Revenue Next Year
- NDLS $1.18
- IRD $29.37
- P/E Ratio
- NDLS N/A
- IRD N/A
- Revenue Growth
- NDLS N/A
- IRD N/A
- 52 Week Low
- NDLS $0.55
- IRD $0.81
- 52 Week High
- NDLS $2.36
- IRD $2.34
- Technical
- Relative Strength Index (RSI)
- NDLS 43.04
- IRD N/A
- Support Level
- NDLS $1.20
- IRD N/A
- Resistance Level
- NDLS $1.57
- IRD N/A
- Average True Range (ATR)
- NDLS 0.13
- IRD 0.00
- MACD
- NDLS -0.04
- IRD 0.00
- Stochastic Oscillator
- NDLS 4.44
- IRD 0.00
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.